Y-mAbs Therapeutics, Inc.
YMAB
$8.54
$0.0050.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.97% | 21.62% | -587.25% | 9.67% | -46.76% |
| Total Depreciation and Amortization | -65.36% | -55.35% | -36.65% | -27.98% | -31.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -73.79% | -41.70% | 170.58% | 7.10% | 11.31% |
| Change in Net Operating Assets | -32.27% | -220.82% | 87.04% | -298.57% | 392.89% |
| Cash from Operations | 454.03% | -98.76% | 76.73% | -697.09% | 106.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -81.11% | -80.61% | 886.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -81.11% | -80.61% | 886.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -300.00% | -- | -92.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.60% | -139.75% | 88.81% | -623.77% | 143.58% |